Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 27
Summary
- Conditions
- Esophageal Cancer
- Gastric Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01522768
- Collaborators
- Boehringer Ingelheim
- University of Southern California
- Dana-Farber Cancer Institute
- United States Department of Defense
- Investigators
- Principal Investigator: Yelena Janjigian, MD Memorial Sloan Kettering Cancer Center
Get Well Soon